A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32792628.
- Also identified by DOI 10.1038/s41467-020-17892-0 and PMC identifier 7426916.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.
Medical subject headings
- Antibodies, Neutralizing
- Betacoronavirus
- Clinical Laboratory Techniques
- Coronavirus Infections
- Pneumonia, Viral
- Viral Vaccines